[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spondylitis-ankylosing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spondylitis-ankylosing":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,81,113,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":4,"leadSponsor":42,"locationsCount":45},"100165130","natural-history-and-development-of-spondyloarthritis-100165130",false,"NCT01422694","Natural History and Development of Spondyloarthritis","Studies on the Natural History and Pathogenesis of Spondyloarthritis","* INCLUSION CRITERIA\n\nTo be eligible for follow-up visits, patients must meet the Inclusion Criteria, but not the Exclusion Criteria. Subjects will provide informed consent and then be evaluated either in the outpatient or inpatient unit of the NIH Clinical Center.\n\n* Subjects with known or suspected SpA.\n* Family members of individuals with known or suspected SpA. Family members will not be asked to submit to bone marrow aspiration or interruption of therapy.\n* Controls for clinical, cellular, molecular, and biochemical assays, and genetic evaluation will be enrolled. Individuals who undergo phlebotomy specifically to provide a control specimen will be 6 years of age or older, and not pregnant.\n* Minor healthy volunteers undergoing imaging (SI and\u002For WB MRI) must be old enough to complete the procedure without sedation. Generally this requires that they be at least 6 years of age, so no healthy volunteers under age 6 will be enrolled.\n* Pregnant people with SpA are allowed to enrolled. Pregnant people will not be asked to undergo an MRI and will not be asked to submit to skin biopsy or bone marrow aspiration.\n\nEXCLUSION CRITERIA\n\n* Inability to provide informed consent or, in the case of minors, unavailability of a parent or guardian.\n* Presence of any medical condition that would, in the opinion of the investigators, confuse the interpretation of the study.\n* Unavailability, or inability to comply with the schedule for follow-up visits.\n* Children under the age of 2 years old.\n\nThe vast majority of minors with SpA or suspected SpA will be 6 years of age or older. However, it is possible that children younger than age 6 will be evaluated. If children under age 6 are referred for evaluation, we will ensure that they do not have any acute or chronic comorbidity that would preclude them from being safely evaluated at the NIH Clinical Center. Such patients would be referred to other appropriate pediatric hospitals.\n\nBased on estimates of the incidence and prevalence of SpA in the pediatric and adult populations we set the accrual ceiling up to 2000. We hope to enroll up to 100 patients per year.",true,"ALL","2 Years","99 Years",{"count":21,"type":22},2000,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- Spondyloarthritis (SpA) is a group of bone and joint disorders that may cause back and joint pain and stiffness. In some cases, SpA can lead to abnormal bone growth affecting the joints and spine. Some patients have SpA without ever developing these growths, while others develop them after only a few years. Researchers are interested in studying people with SpA and their relatives to determine which people are more likely to develop more severe conditions.\n\nObjectives:\n\n\\- To identify symptoms and medical tests that can help determine whether a person with SpA is at risk for developing more severe forms of the disease.\n\nEligibility:\n\n* Individuals of any age who have been diagnosed with SpA.\n* Healthy volunteer relatives (at least 6 years of age) of the individuals with SpA.\n\nDesign:\n\n* Participants will be screened with medical records and family medical histories, and will be invited to the clinical center for the study.\n* Participants with SpA will have a physical exam and medical history, including a study of joint movement, blood and urine tests, and questionnaires about pain and quality of life.\n* Participants with SpA will have imaging studies, including magnetic resonance imaging (MRI). Other samples such as skin tissue and bone marrow may also be collected for study.\n* Healthy volunteers will provide a blood sample and cheek cell samples.\n* No treatment will be provided, although treatment options will be discussed.",[26,27],"Arthritis","Spondylitis, Ankylosing",[29,30,31,32,33,34],"Sacroiliitis","Ankylosing Spondylitis","Spondyloarthritis","HLA-B27","Enthesitis-Related Arthritis","Natural History","RECRUITING","2026-06-27",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"2011-08-12",{"name":43,"class":44},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100636097","exploratory-investigation-of-the-acceptance-and-utility-of-14-day-trial-periods-and-application-related-outcome-measurement-abem-within-the-routine-prescription-of-the-diga-axia-100636097","NCT07561255","Exploratory Investigation of the Acceptance and Utility of 14-day Trial Periods and Application-related Outcome Measurement (AbEM) Within the Routine Prescription of the DiGA Axia.","Real-world Quality Management Study With Axia to Evaluate the Measures of the DigiG (RAEMD Study)","RAEMD","Inclusion Criteria:\n\n* Willingness to use Axia.\n* Axia indication area.\n* Willingness to activate via onboarding brochure.\n\nExclusion Criteria:\n\n* Absence of the inclusion criteria","18 Years",{"count":56,"type":22},200,"INTERVENTIONAL",[59],"NA","This prospective, multicenter, controlled real-world quality management study explores the acceptance and utility of two measures discussed in the context of the German Digital Act (DigiG) for the digital health application (DiGA) Axia: a 14-day trial period and an application-related outcome measurement (AbEM). Patients with axial spondyloarthritis in Axia's indication area who are eligible for prescription in routine care will receive one of two onboarding brochure versions in a 1:1 allocation: either the standard access procedure or immediate 14-day trial access until the health insurance activation code arrives. The manufacturer will analyze aggregated anonymized data to compare voucher redemption and app activation frequencies between groups and to assess acceptance and return rates of a voluntary five-item AbEM questionnaire at weeks 6 and 12. Secondary analyses will descriptively evaluate AbEM results and anonymized usage data.",[27,62],"Mobile Phone Use",[64,65,66,67,68,69],"axial spondyloarthritis","mobile health","digitalization","onboarding","real-world","therapeutic app","2026-04-27",{"date":72,"type":39},"2026-05-01",{"date":74,"type":39},"2026-04-10",{"date":76,"type":22},"2027-04-10",{"name":78,"class":79},"Wuerzburg University Hospital","OTHER",7,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":91,"conditions":92,"keywords":99,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":45},"100580823","effects-of-phytocannabinoids-on-immune-response-and-autophagy-during-chronic-immune-mediated-inflammatory-diseases-100580823","NCT06842316","Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases","In Vitro Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases","pCB-IMIDs","Inclusion Criteria:\n\n1. Male or female ≥ 18 years old\n2. Diagnosis confirmed by a rheumatologist of RA or spondyloarthropathy (with or without IBD) or psoriatic arthritis (with or without active psoriasis) or systemic lupus erythematosus or Sjögren's disease\n3. Patient who has expressed consent to participate in the study\n4. Patients affiliated to social security\n5. Treatments authorized as part of routine care: non-steroidal anti-inflammatory drugs (NSAIDs), level 1 to 3 analgesics, local corticosteroids, oral corticosteroid therapy (daily dose ≤15 mg\u002Fd), 5-aminosalicylic acid, salazopyrine, methotrexate, leflunomide, hydroxychloroquine, biotherapies and targeted therapies.\n\nExclusion Criteria:\n\n1. Patient who received intravenous corticosteroid therapy less than 4 weeks ago\n2. Patient receiving oral corticosteroid therapy with a daily dose \\>15 mg\u002Fday\n3. Consumption of CBD and\u002For recreational cannabis and\u002For positive saliva test for cannabis consumption and\u002For CBD\n4. Pregnant and lactating women\n5. Persons under guardianship or curatorship",{"count":90,"type":22},100,"Cannabis, in addition to its psychotropic properties, could have anti-inflammatory and immunomodulatory effects. Phytocannabinoids (pCBs) are a group of molecules naturally secreted by the cannabis plant. The major pCBs are cannabidiol (CBD) and Δ9-tetrahydrocannabinol Δ9 (THC). Only THC has psychotropic effects, which CBD does not have. Alongside these two main components, there is a wide variety of other molecules, such as other pCBs and terpenes which could increase the effects on immune system through synergistic interactions between these different compounds (\"entourage effect\").In vivo, pCBs essentially interfere with the endocannabinoid system, acting on many ubiquitous receptors, present on a significant number of different cell types. Numerous published studies show that pCBs have immunomodulatory and anti-inflammatory properties by acting on several of these receptors, whether through modulation of the immune response of different cell types, effects on cytokine networks, reduction of innate and adaptive responses and\u002For impact on cell survival or death (autophagy, proliferation\u002F apoptosis). The Immune-Mediated Inflammatory Diseases (IMIDs) affect 5 to 7% of the general population in Western countries, involve different organs (joints, skin, digestive tract) but share the same inflammatory mechanisms resulting from a dysregulation of the immune response. Our research focuses on the identification of the most effective phytochemical profile of pCBs, allowing an optimal effect on chronic inflammatory pathologies of interest among immune-mediated chronic inflammatory diseases (IMIDs). The pCB-IMIDs project is therefore part of an innovative translational project, around new therapeutic applications of medical cannabis (CannAppIMIDs). In our study, we will include 100 patients with one of IMIDs among Rheumatoid Arthritis, spondylarthritis, psoriatic arthritis, Sjogren disease and systemic lupus, at different stage and with different treatments. After patient's consent we will collect for research purposes an additional 40 ml of blood during a routine care blood test. Mononuclear and polynucleated blood cells will be exposed in vitro to different full-spectrum pCB extracts (full spectrum extract) including a CBD dominant and low THC extract (\\\u003C0.2%), 1 dominant THC extract, 1 balanced THC\u002FCBD extract and 1 dominant CBG extract. In this cross-sectional study, our objective will be to assess the biological effects of different pCB compositions on inflammatory profiles (concentrations of pro and anti-inflammatory cytokines and chemokines) and modulations of expression profiles (autophagy, apoptosis, and cannabinoid receptor expression profile).",[93,27,94,95,96,97,98],"Inflammatory Disorder of Immune System","Arthritis, Rheumatoid","Arthritis, Psoriatic","Inflammatory Bowel Diseases","Sjogren's Syndrome","Lupus Erythematosus, Systemic",[100,101,102,103],"IMIDs","phytocanabinoid","inflammatory effect","blood cells","2025-12-22",{"date":106,"type":39},"2025-12-30",{"date":108,"type":39},"2025-04-10",{"date":110,"type":22},"2027-04-09",{"name":112,"class":79},"Centre Hospitalier Régional d'Orléans",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":45},"100592813","spondylo-arthritis-screening-tool-among-patient-suffering-from-inflammatory-bowel-disease-100592813","NCT06998316","Spondylo-arthritis Screening Tool Among Patient Suffering From Inflammatory Bowel Disease","Linguistical Validation of a Spondylo-arthritis Screening Tool for Patients Suffering From Inflammatory Bowel Disease","QUESAM","Inclusion Criteria:\n\n* Patient with an inflammatory bowel disease according to gastroenterologist\n\nExclusion Criteria:\n\n* No exclusion criteria\n* Difficulty for understanding or reading french\n* Persons covered by articles L1121-5 to L1121-8 of the French Public Health Code\n* Patients with no social security coverage.\n* Patients refusing to participate voluntarily.",{"count":122,"type":22},220,"The QUESAM study aims to translate into French and validate the traduction of 2 screening questionnaires for spondylo-arthritis among people with inflammatory bowel disease.\n\nDETAIL (DETection of Arthritis in Inflammatory boweL diseases) and IBIS-Q (Inflammatory Bowel disease Identification of Spondyloarthritis Questionnaire) questionnaires are built to determine which patients might benefit from a rheumatologic consultation, for a potential rheumatologic inflammatory disease.\n\nThe investigators will translate the 2 questionnaire in french thanks to an external translation company, from english to french, then back to english to make sure the translation is correct.\n\nThen, the main question is:\n\nis there a conceptual and semantic equivalence beetween the original english questionnaire and the french-translated one.\n\nParticipant will answer the 2 screening questionnaire, one initial time during a consultation, and a second time after 1 month.",[125,96,126,127,27],"Spondylarthritis","Crohn Disease","Ulcerative Colitis",[129,126,127,96,130],"spondylarthritis","screening tools","NOT_YET_RECRUITING","2025-05-21",{"date":134,"type":39},"2025-05-31",{"date":136,"type":22},"2025-05",{"date":138,"type":22},"2026-07",{"name":140,"class":79},"University Hospital, Grenoble",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":158,"locationsCount":45},"100418678","characterization-of-immunogenicity-of-tnf-inhibitors-in-arthritis-patients-with-poorer-treatment-response-100418678","NCT04731831","Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.","Characterization of Immunogenicity of Tumor Necrosis Factor Inhibitors in Arthritis Patients With Poorer Treatment Response Due to Gender, Obesity and Smoking Status.","Inclusion Criteria:\n\n* Patients \\> 18 years\n* Diagnosed with RA, PsA or AS.\n* Starting treatment with infliximab or adalimumab.\n* Co- treatment with csDMARD or glucocorticoid is acceptable.\n* No new bDMARD is initiated at the time of sampling.\n\nExclusion Criteria:\n\n\\-",{"count":149,"type":22},120,"The aim of the study is to explore whether the influence of gender, tobacco smoking and obesity on treatment response in tumor necrosis factor inhibitors (TNFIs) can be explained by high degree of inflammation, human leucocyte antigen (HLA) type, autoantibodies, TNF and TNFI concentration and presence of ADA.",[94,95,27],"2024-06-27",{"date":154,"type":39},"2024-06-28",{"date":156,"type":39},"2020-08-01",{"date":106,"type":22},{"name":159,"class":79},"Aalborg University Hospital"]